Eric Dube, CEO of Travere Therapeutics, sold 60,000 shares for $1.856 million, a 12.17% stake reduction, under a Rule 10b5-1 plan. Despite this, analysts maintain a "Moderate Buy" rating with a target price of $39.00, and some institutional investors have boosted their stakes.

NodeGuardian

2026-04-14 23:30:55

Abstract generation in progress

Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube sold 60,000 shares of the company’s stock on April 1st for $1.856 million, reducing his stake by 12.17%. The sale was pre-arranged under a Rule 10b5-1 plan. Despite this insider selling, the stock maintains a “Moderate Buy” consensus rating from analysts with a target price of $39.00, and institutional investors like State Street and Wellington have recently increased their positions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes

Reward
1
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
111.75K Popularity
#
GateMarchTransparencyReport
36.64K Popularity
#
GoldmanSachsFilesBitcoinIncomeETF
771.44K Popularity
#
USBlocksStraitofHormuz
744.24K Popularity
#
WCTCTradingChallengeShare8MUSDT
501.74K Popularity

Sitemap

Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 60,000 Shares

Trending Topics

GatePreIPOsLaunchesWithSpaceX

GateMarchTransparencyReport

GoldmanSachsFilesBitcoinIncomeETF

USBlocksStraitofHormuz

WCTCTradingChallengeShare8MUSDT

Pin